Primity Bio
- Company typePrivate
- Founded2010
- HeadquartersFremont, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Primity Bio does
Primity Bio is a specialised contract research organisation focused on biomarker and immune monitoring services, founded in 2010 and headquartered in Fremont, California. The firm serves pharmaceutical and biotechnology clients developing therapeutics across oncology, immunology, neurosciences, infectious diseases, cell therapy, and antibody-drug conjugates (ADCs). Per the broader source data, Primity Bio's operations appear to sit within the CellCarta global CRO network, which delivers integrated multi-platform laboratory services spanning biomarker development, immune monitoring, proteomics, genomics, histopathology, bioinformatics, and lab logistics. Customers engage through enterprise field sales relationships and receive support across preclinical through clinical phases, including companion diagnostic (CDx) development.
Primity Bio firmographics
Firmographics- Name
- Primity Bio
- Legal name
- CellCarta
- Website
- https://primitybio.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Primity Bio industry classification
Industry- Product category
- Contract Research Organization (Biomarker & Immune Monitoring Services)
- NAICS
- Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industries
- Single-Cell & Spatial Omics Services (HLAGANAC), Proteomics & Biomarker Analytical Testing (HLAGADAG), Proteomics & Mass Spectrometry Services (HLAGANAB)
Keywords
Where Primity Bio is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Primity Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Contract Research Services: CellCarta generates revenue through providing contract research organization (CRO) services to pharmaceutical and biotech companies. Services span biomarker development, immune monitoring, proteomics, genomics, histopathology, bioinformatics, and lab logistics. Revenue is generated through project-based contracts with pharmaceutical clients across various therapeutic areas including oncology, immunology, neurosciences, and infectious diseases.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based project pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Primity Bio product offering
Product offeringCore offering
Primity Bio is a specialised provider of biomarker and immune monitoring services, operating as a contract research organization that delivers laboratory testing, multi-omics analysis (proteomics, genomics, histopathology), and integrated sample logistics to pharmaceutical and biotechnology companies developing therapeutics across oncology, immunology, neurosciences, infectious diseases, cell therapy, and antibody-drug conjugates. Its offerings are anchored in proprietary platforms including Ella™ automated ELISA multiplexing, CellEngine® cytometry analysis software, Olink™ PEA Technology, and the Antigen Atlas™ antigen database, with global PBMC processing capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Ella™: Next-generation automated ELISA multiplexing technology
- CellEngine®
- Antigen AtlasTM Database
Products and services
- Biomarker Solutions End-to-end biomarker development and validation services for pharmaceutical and biotech companies, including clinical biomarker assays, discovery and preclinical biomarker work, and mass spectrometry-based biomarker quantification. Designed for drug development programs across therapeutic areas such as oncology, immunology, and neurosciences.
- Immune Monitoring Specialized immune monitoring services including Basophil Activation Test (BAT), cell enumeration, cellular phenotyping, cellular proliferation/cell cycling, intracellular cytokine staining (ICS), fluorescence-activated cell sorting (FACS), MDSC assays, and receptor occupancy (RO) assays. Used by pharmaceutical and biotech clients to evaluate immune responses during clinical drug development.
- Proteomics Services Proteomics testing services for pharmaceutical and biotech clients, including B-cell maturation antigen (BCMA) assays, FFPE biomarker quantification, immunoassays, immuno-MRM assays, pharmacokinetics by mass spectrometry, and advanced unbiased proteomics for translational discovery.
- Genomics Services Genomics testing services including digital PCR (dPCR), quantitative PCR, RNA sequencing (RNA-seq), genomic assays by mutations, and next-generation sequencing (NGS). Provided to pharmaceutical and biotech clients for translational and clinical research programs.
- Histopathology Services Histopathology services including digital pathology, immunohistochemistry-immunofluorescence (IHC-IF), an IHC biomarker menu, and in situ hybridization (ISH), delivered by a dedicated pathology team. Targeted at pharmaceutical and biotech clients needing tissue-based analyses for drug development.
- Data Analysis Services Bioinformatics, biostatistics, and genomic data analysis services for pharmaceutical and biotech clients, complemented by the Antigen Atlas™ antigen database and CellEngine® cytometry analysis software for downstream interpretation of complex laboratory data.
- Regulatory Expertise Services Regulatory-focused services for pharmaceutical and biotech clients, including companion diagnostic (CDx) development, quality management systems, and clinical laboratory services to support drug-diagnostic co-development and regulatory submissions.
- Lab Logistic Services Integrated lab logistics and sample management services, including biorepository services, clinical site training, Global PBMC Processing Services, kitting solutions, and sample logistics for clinical trials. Provided to pharmaceutical and biotech sponsors requiring reliable specialty sample handling.
Companies that use Primity Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Primity Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Primity Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Pillar BiosciencescoreCellCarta and Pillar Biosciences collaboration to accelerate FGFR NGS assay development from RUO (Research Use Only) to IUO (Investigational Use Only) for a global Phase 3 oncology trial. This partnership demonstrates joint product development and co-development capabilities for regulatory-grade diagnostics.
- Leica BiosystemscoreStrategic collaboration between Leica Biosystems and CellCarta for advancing precision diagnosis and treatment, co-promoting the development of companion diagnostics. This partnership combines Leica Biosystems' precision diagnosis capabilities with CellCarta's CDx services to advance companion diagnostic development for pharmaceutical clients.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Primity Bio competitors and assessment
Company assessmentRegional players
- NeoGenomics: US-centric clinical oncology and immuno-oncology laboratory with strong flow cytometry, IHC, and molecular offerings — a more regional/biomarker-focused comparator for CellCarta's oncology services.
Broad incumbents
- Medpace Holdings: Mid-to-large clinical CRO with in-house central lab and biomarker offerings in oncology and immunology — directly comparable therapeutic-area mix and sponsor base.
- Labcorp Drug Development: One of the largest global CROs (formerly Covance) offering central lab, biomarker, genomic, and immunoassay services across all therapeutic areas — overlaps with CellCarta across the entire biomarker stack but at much greater scale.
- Charles River Laboratories: Major preclinical and clinical CRO with growing biomarker and immune-monitoring capabilities; competes with CellCarta especially in cell therapy, oncology, and immunology client programs.
- ICON plc: Large clinical CRO with central-lab and biomarker capabilities (post-PRA Health Sciences merger); competes with CellCarta on global pharma trial lab services.
- Eurofins Scientific: Global lab-services platform with extensive biomarker, genomic, proteomic and clinical-trial-support testing — overlapping service menu with CellCarta across pharma clinical-trial lab work.
- Bio-Techne: Life-science tools and services company with reagents, assays, and contract services (including the ExoDx and ProteinSimple franchises) that overlap with CellCarta's proteomics, genomics, and immunoassay offerings.
Direct peers
- Pharmaron: Integrated CRO with strong biomarker, immunoassay, and bioanalytical services for global pharma; comparable in therapeutic-area breadth and modality coverage to CellCarta.
- Celerion: Specialized CRO focused on early-phase clinical pharmacology and bioanalytical/biomarker services for pharma and biotech — comparable as a focused biomarker and immune-monitoring services provider.
- IQVIA (Q² Solutions): Global CRO with a dedicated Q² Solutions biomarker and genomic laboratories business that competes head-to-head with CellCarta in flow cytometry, genomics, and immunoassay services for pharma and biotech trials.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights5 records
Customer concentration
Primity Bio social profiles
Digital presencePrimity Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Primity Bio leadership team
Management profileNumber of profiles
Primity Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Primity Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Primity Bio
What does Primity Bio do?
Primity Bio is a specialised provider of biomarker and immune monitoring services, operating as a contract research organization that delivers laboratory testing, multi-omics analysis (proteomics, genomics, histopathology), and integrated sample logistics to pharmaceutical and biotechnology companies developing therapeutics across oncology, immunology, neurosciences, infectious diseases, cell therapy, and antibody-drug conjugates. Its offerings are anchored in proprietary platforms including Ella™ automated ELISA multiplexing, CellEngine® cytometry analysis software, Olink™ PEA Technology, and the Antigen Atlas™ antigen database, with global PBMC processing capabilities.
When was Primity Bio founded?
Primity Bio was founded in 2010. It employs 1 to 10 people.
Where is Primity Bio based?
Primity Bio is headquartered in Fremont, United States, in the North America region.
How does Primity Bio make money?
One revenue line is on record: contract Research Services.
Who are Primity Bio's main competitors?
NeoGenomics is listed as a regional player. Broad incumbents are Medpace Holdings, Labcorp Drug Development, Charles River Laboratories, ICON plc, Eurofins Scientific and Bio-Techne. Direct peers are Pharmaron, Celerion and IQVIA (Q² Solutions).
Does Primity Bio have an API?
No public API is recorded for Primity Bio.
What industry is Primity Bio in?
Primity Bio's product category is Contract Research Organization (Biomarker & Immune Monitoring Services). Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGANAC, Single-Cell & Spatial Omics Services. Its NAICS code is 6215 and its SIC code is 8071.